Faham Doaa El, Ali Khaled, Din Adel Salah El, Bibars Mamdouh, Azmy Osama
Reproductive Health Research Department, National Research Centre, Cairo, Egypt.
Obstetrics and Gynecology Department, Ain Shams University Maternity Hospital, Cairo, Egypt.
J Reprod Infertil. 2019 Apr-Jun;20(2):89-94.
A reduction in intra-ovarian vascular resistance is necessary to achieve pregnancy in a natural cycle. The aim of this RCT was to detect whether a vasodilator calcium channel blocker, amlodipine, could increase the pre-ovulatory follicular blood flow, enhance follicular maturation in women with PCOS and improve ovulatory outcome.
Sixty women received induction by clomiphene citrate (CC); thirty were given amlodipine (Amlodipine group) and the other 30 women were given placebo (Placebo group). The pattern of pre-ovulatory follicle blood flow was studied by color and power Doppler ultrasonography pre and post drug administration. Independent t-test was used to compare mean values of the 2 groups. The p<0.05 is considered statistically significant.
When comparing the Doppler effect of amlodipine versus placebo in the treatment cycle, it was found that mean value of ovarian arteries (OA) pulsatility index was lower in amlodipine group but it didn't reach statistical significance (p= 0.063); however, the mean value of OA resistance index reached statistical significance (p=0.028) in amlodipine group. Moreover, in the second cycle, endometrial thickness was significantly higher (p=0.006) in women of the amlodipine group when compared to those of the placebo group. At least one sonographically detectable mature follicle (≥18 ) was observed in 54.5% (36/66) during the first cycle. At the second cycle, this proportion significantly rose to 86.7% (26/30) in the amlodipine group, but marginally and non-significantly to 56.7% (17/30) in the placebo group.
Amlodipine as calcium channel blocker was proved to have a role in improving ovarian blood flow at the time of ovulation and enhancing follicular maturation and thus, it may increase the chances of conception.
在自然周期中,降低卵巢内血管阻力对于实现妊娠是必要的。本随机对照试验的目的是检测血管扩张剂钙通道阻滞剂氨氯地平是否能增加排卵前卵泡的血流,促进多囊卵巢综合征女性的卵泡成熟并改善排卵结局。
60名女性接受枸橼酸氯米芬(CC)诱导;30名给予氨氯地平(氨氯地平组),另外30名女性给予安慰剂(安慰剂组)。在给药前后通过彩色和能量多普勒超声研究排卵前卵泡血流模式。采用独立t检验比较两组的均值。p<0.05被认为具有统计学意义。
在治疗周期中比较氨氯地平和安慰剂的多普勒效应时,发现氨氯地平组卵巢动脉(OA)搏动指数的均值较低,但未达到统计学意义(p = 0.063);然而,氨氯地平组OA阻力指数的均值达到了统计学意义(p = 0.028)。此外,在第二个周期中,氨氯地平组女性的子宫内膜厚度显著高于安慰剂组(p = 0.006)。在第一个周期中,54.5%(36/66)的患者至少观察到一个超声可检测到的成熟卵泡(≥18)。在第二个周期中,氨氯地平组这一比例显著上升至86.7%(26/30),而安慰剂组仅略有上升至56.7%(17/30),无统计学意义。
钙通道阻滞剂氨氯地平被证明在改善排卵时的卵巢血流和促进卵泡成熟方面具有作用,因此,它可能增加受孕几率。